Clinical trials: Leukemia Cutis

Acute Myeloid Leukemia, Leukemia Cutis

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

• Completed
• Age: Up to 29 years
• Phase 3
• Injection or infusion
• Results posted

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia.

Conditions

Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma

Trial name

NCT01371981

Testing

Asparaginase, Bortezomib, Cytarabine

Where

220 sites in United States, Australia and 3 more

Volunteers

1,645 people

Sponsor

National Cancer Institute (NCI)